Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations

ILD is an underrecognized but clinically significant toxicity of CDK4/6i, requiring early diagnosis and prompt intervention to prevent severe respiratory compromise. A high index of clinical suspicion, prompt diagnosis, and rapid treatment strategies are crucial, particularly in elderly patients, to minimize ILD-associated risks and complications. Further research is needed to establish predictive biomarkers and optimize management guidelines for CDK4/6i-induced ILD.